Occasionally you will see headline bundles that sound generous at first glance
3C and D, patients in the LGSH group exhibited significantly improved OS and DFS compared to those in the HGSH group (median OS: 70 months vs
The analysis included data from 18,742 patients with type 2 diabetes mellitus (T2DM) receiving 5.0mg, 10.0mg, or 15.0mg once-weekly subcutaneous tirzepatide or 0.5mg, 1.0mg, or 2.0mg once-weekly subcutaneous semaglutide for at least 12 weeks
10.1007/s13105-022-00939-9 18 EdwardsC
Clinical trials for tirzepatide showed that injection site reactions like redness, itching, or slight swelling are among the most common side effects
The shortage is no longer the basis for an exemption, and the TGA's position is that compounded semaglutide supply was never appropriately authorised under the compounding provisions even during shortage conditions